NewslettersHuman Immunology NewsHigh Efficacy of huCD20-Targeted AcTaferon in Humanized Patient Derived Xenograft Models of Aggressive B Cell LymphomaBy Jamie Kang - June 4, 2024083Researchers explored the antitumoral potential of the humanized huCD20-Fc-AFN in 5 different humanized patient-derived xenograft (PDX) models of huCD20+ aggressive B non-Hodgkin lymphomas.[Experimental Hematology & Oncology]Full ArticleGraphical Abstract